Trial Profile
A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Pixantrone (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Cell Therapeutics; CTI BioPharma
- 02 Oct 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 02 Oct 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 08 Jul 2009 Additional lead trial investigator (Gorbatchevsky I) identified as reported by ClinicalTrials.gov (NCT00551239).